Previous 10 | Next 10 |
Harmony has done very well monetizing their first asset. They have to start planning for the future. Expanding Wakix labels and acquiring new, late stage assets, are key steps. For further details see: Harmony Biosciences: Steady Revenue Generator Looking For A Future
Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay. The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA templ...
In a bear market, Krystal still shows that strong execution can be lucrative. They will file a BLA this quarter. The market potential is huge. For further details see: Krystal Biotech: High Potential, Buy-At-Dips Stock
How similar will the next three or five years look from the years that immediately preceded the pandemic? And what are the implications for us as global equity investors? We don’t expect anything like the hyperinflation and stagflation we experienced in the 1970s; our outlook s...
Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...
Final data from the phase 3 REGENERATE study, using Ocaliva for the treatment of patients with NASH fibrosis, is expected any day now. If all goes well with clinical data, Intercept expects a pre-submission meeting with the FDA in June of 2022. Results from the phase 3 REVERSE stu...
Aurinia and its partner OPEL expect a decision from the EMA in the 2nd half of 2022 on whether or not Lupkynis (voclosporin) will be approved for lupus nephritis in the European territories. About $21.6 million in net revenue was generated for Q1 of 2022, due to sales of Lupkynis; if ...
Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was...
Novavax reported an underwhelming Q1 earnings card. Despite reiterating its FY22 guidance, the consensus estimates have been downgraded. The market is losing confidence in management's ability to deliver. Therefore, if Novavax continues to miss the estimates, we believe it could lead ...
Today, we revisit advance wound care name Organogenesis Holdings for the first time since late in 2020. This small cap healthcare concern is already profitable and continues to build out its product portfolio. A full investment analysis follows in the paragraphs below. For f...
News, Short Squeeze, Breakout and More Instantly...
Global X Genomics & Biotechnology ETF Company Name:
GNOM Stock Symbol:
NYSE Market:
2024-07-11 22:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-01 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...